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Genotype–phenotype correlationCongenital dyserythropoietic anemia type II, a recessive disorder of erythroid differentiation, is due to muta-
tions in SEC23B, a component of the core trafﬁcking machinery COPII. In no case homozygosity or compound
heterozygosity for nonsense mutation(s) was found. This study represents the ﬁrst description of molecular
mechanisms underlying SEC23B hypomorphic genotypes by the analysis of ﬁve novel mutations. Our ﬁndings
suggest that reduction of SEC23B gene expression is not associated with CDA II severe clinical presentation; con-
versely, the combination of a hypomorphic allele with one functionally altered results in more severe phenotypes.
We propose a mechanism of compensation SEC23A-mediated which justiﬁes these observations.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Congenital dyserythropoietic anemia type II (CDA II, OMIM 224100)
is a genetic hyporegenerative anemia characterized by ineffective
erythropoiesis and distinctmorphological abnormalities of the erythro-
blasts in the bone marrow (BM). Anemia of variable degree, jaundice
and splenomegaly are common clinical ﬁndings [1]. This condition
belongs to COPII-related human genetic disorders [2]. It is due tomuta-
tions in SEC23B (chr 20p11.23), a component of COPII complex, the core
trafﬁcking machinery of the endoplasmic reticulum-Golgi [3]. Approxi-
mately 60 different causative mutations have been described, localized
along the entire coding sequence of the gene [1,4–6]. Themost frequent
are nucleotide substitutions (75% missense/nonsense), whereas frame-
shift and splicingmutationswere observed in 15% and 10% respectively.
The vast majority of patients have two mutations (in the homozygous
or compound heterozygous state), according to the pattern of autoso-
mal recessive inheritance. In no case homozygosity or compound het-
erozygosity for two nonsense mutations was found, a situation likely
to be lethal. However, few cases with two hypomorphic mutations
have been described so far [4,5].vanzate, Via Gaetano Salvatore
).
-ND license.Here we characterize three novel CDA II cases, two of them with
fully hypomorphic genotype. We demonstrated a compensatory mech-
anism SEC23A-mediated of SEC23B hypo-expressed alleles.
Material and methods
Patients and mutational screening
Diagnosis of CDA II was based on history, clinical ﬁndings, laboratory
data, morphological analysis of aspirated bone marrow and whenever
possible on evidence of hypoglycosylated band 3 by SDS-PAGE. Samples
were obtained after informed consent for the studies, according to the
Declaration of Helsinki. Whenever possible, relativeswere investigated.
Genomic DNA and mutational screening were performed as previously
described [4].
In silico and ex vivo analyses on mRNA
Prediction analyses for splice sitemutationswere performed byweb
server tools, splice site prediction by neural network (http://www.
fruitﬂy.org/seq_tools/splice.html) and human splicing ﬁnder (http://
www.umd.be/HSF/) (Table 2).
RNA isolation from peripheral blood mononuclear cells (PBMCs),
cDNA preparation and quantitative real-time (qRT)-PCRwere performed
as described [7]. Relative gene expression was calculated by using the
2−ΔCt method, while the mean fold change=2−(average ΔΔCt) was
Table 1
Clinical data of CDA II patients.
A-II.1 B-II.1a C-II.1
Gender (male/female) F F M
Age at diagnosis (years) 11 35 9
Onset of symptoms (years) 8 At birth 3
Consanguinity (yes/no) n.a. No n.a.
Geographical origin Sweden Italy USA
RBC (×106/μL) 3.1 3.3 3.0
Hb (g/dL) 8.8 10.5 7.2
Ht (%) 27.0 29.0 23.0
MCV (fL) 87.0 90.0 77.0
MCH (pg) n.a. 32.0 24.2
MCHC (g/dL) 33.2 35.5 31.4
RDW (%) n.a. 17.3 20.2
Retics abs count (×103/μL) 103 111 34
PLT (×103/μL) 204 311 334
Ferritin (ng/mL) 45 168 82
Transfusion N/year 1/1 n.a. –
Splenomegaly (yes/no) Yes Yes Yes
n.a., not available.
a Data before splenectomy.
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internal control [8].
SEC23B coding sequencewas covered by ﬁve overlapping PCR frag-
ments and ampliﬁed by KAPA2G Robust HotStart ReadyMix (Kapa
Biosystems, Cape Town, South Africa). Sequence primers are available
on request (achille.iolascon@unina.it).Fig. 1. SEC23B novelmutations and analysis of their effect on gene and protein expressions. Pan
mutations are novel, except the nucleotide replacement c.1489C>T (p.R497C). Panel B. SEC23B
reduced SEC23B expression compared to control group (CTRs, 4.88±0.37; A-II.1, 0.16±0.01, p
mean±SE. p Value has been calculated by Student t test. Panel C.WBanalysis showed a reduced
The histograms show the densitometric quantiﬁcation. Sizes (in kDa) are on the left.Protein analysis
Protein extraction from PBMCs and western blotting (WB) were
performed as previously described [7,9]. A speciﬁc rabbit anti-SEC23B
antibody (1:500) (BioLegend, San Diego, CA) was used. Mouse anti-
β-actin antibody (1:5000) (Sigma-Aldrich, Milan, Italy) was used as
the control for equal loading. WB analysis on gradient was performed
by precast gel (Biorad, Milan, Italy). Particularly, 60 μg of total extract
proteins was loaded into each lane and was separated by gradient 4–
15% SDS PAGE bisacrylamide gel, followed by transfer to PVDF mem-
branes (Biorad, Milan, Italy).Results
Clinical and genetic features
The clinical features of the three probands are presented in Table 1.
Onset symptoms (anemia, jaundice) were in the ﬁrst decade of life. At
diagnosis, they exhibited a normocytic anemia with a reticulocytosis
not corresponding to the degree of anemia. Patient B-II.1was ﬁrstly di-
agnosed with hereditary spherocytosis. She subsequently underwent
splenectomy with a slight improvement of anemia. BM examination
of patients A-II.1 and C-II.1 showed erythroid hyperplasia, with bi-
and tri-nucleated erythroblasts (Fig. 1s). Patients A-II.1 and B-II.1
exhibited a milder phenotype than patient C-II.1, with a higher ab-
solute reticulocyte count (Table 1).el A. Inheritance pattern of SEC23Bmutations in three unrelated patients were showed. All
relative expression respect to the reference gene, β-actin, is shown. All patients exhibited a
b0.001; B-II.1, 2.59±0.09, p=0.006; C-II.1, 3.49±0.23, pb0.0001). Data are presented as
expression of SEC23B inCDA II patients of comparable extent to that observedbyqRT-PCR.
Table 2
In silico analysis of intronic mutations.
Nucleotide
changea
Exon
intron
Splice site
type
Predicted effect on mRNA
BDGP HSF
Scoreb Δ (%) Scoreb Δ (%)
c.834+3A>C 7–8 Donor 0.93>null −100 8.88>3.31 −62.7
c.221+163A>G 2–3 Cryptic
donor
Null>0.99 +100 1.79>8.95 +400
c.1404+5G>A 12–13 Donor 0.99>0.66 −33.3 10.67>6.6 −38.1
c.221G>A 2 Donor 0.42>null −100 5.53>−1.37 −124.8
BDGP, BerkeleyDrosophila GenomeProject (http://www.fruitﬂy.org/seq_tools/splice.html).
HSF, Human Splicing Finder (http://www.umd.be/HSF/).
a Nucleotides arenumbered from theA of the ATG initiation codon (ENST00000377475).
b WT sequence score>mutated sequence score.
Fig. 2. gDNA and cDNA sequencing analysis. Panel A. Analysis of both SNPs rs41309927G>A
and rs2273526 C>G highlighted the presence of a double peak (heterozygous state) in the
electropherogram from gDNA of proband A-II.1. Conversely, cDNA sequencing just showed
the presence of the minor allele nucleotides, suggesting an RNA decay mechanism for the
allele c.834+3A>C,which is in ciswithmajor alleles of both SNPs (see Fig. 1A). Panel B. Anal-
ysis of frameshift mutation c.1419_1423insC, p.I473Ifs*47 in proband B-II.1 highlighted the
insertion of the base C and the consequent frameshift in genomic DNA (gDNA); on the con-
trary, themutationwas not found in sequenced cDNA, suggesting an RNA decaymechanism
for this allele. Sequencing analysis of SNP rs2273526 C>G in both gDNA and cDNA conﬁrmed
this suggestion (see Fig. 1A). Panel C. Analysis of the mutation c.221G>A, p.C74Y in CDA II
patient C-II.1 highlighted the presence of a double peak (heterozygous state) in the electro-
pherogram from gDNA; conversely, the mutation was not found in sequenced cDNA,
suggesting an RNA decay mechanism for this mutated allele. Sequencing analysis of SNP
rs17807673 C>T in both gDNA and cDNA conﬁrmed this suggestion (see Fig. 1A).
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intronic mutations (c.834+3A>C; c.221+163A>G; c.1404+5G>A),
one nucleotide insertion (c.1419_1423insC, p.I473Ifs*47) and one G>A
transition (c.221G>A, p.C74Y). None of these mutations is present in
the 1000 Genome project. Accordingly to recessive inheritance pattern,
the patients were compound heterozygotes for two mutations (Fig. 1A).
Role of the intronic mutations on SEC23B gene and protein expression
In the ﬁrst case A-II.1, the association of two splice sitemutations led
to amarked reduction of SEC23B expression atmRNA and protein levels
(Figs. 1B–C). Particularly, the c.834+3A>C mutation is predicted to
abolish the intron 7–8 donor splice site, while the c.221+163A>G to
create a cryptic donor site (Table 2). Accordingly, we found an RNA
decay of the ﬁrst allele in sequenced cDNA (Fig. 2A), and a reduced ex-
pression of the second one (Fig. 2s).
Conversely, patient B-II.1, compoundheterozygous for the splice site
(c.1404+5G>A) and the frameshift (c.1419_1423insC) mutations,
exhibited a mild reduction of mRNA expression compared to healthy
subjects (approximately 50%) (Fig. 1B). WB analysis showed compara-
ble results (Fig. 1C). However no protein product of lower molecular
weight was found as an effect of frameshift mutation, which could lead
to the formation of a truncated protein of 519 amino acids (predicted
molecularweight: 57.8 KDa) (data not shown), leading to the hypothesis
of an RNA decay of this allele. Accordingly, we found the selective expres-
sion of the wild type allele in sequenced cDNA (Fig. 2B).
Patient C-II.1 is a compound heterozygous for two missense varia-
tions: c.1489C>T, p.R497C, already described as CDA II causative mu-
tation [9]; c.221G>A transition, which resulted in the aminoacidic
substitution C74Y. In this case, we suspected SEC23B expression levels
similar to those observed in the control group. However, we found a
reduction of SEC23B gene and protein expression of approximately
30% (Figs. 1B–C). Since c.221G>A transition occurs at the last nucleo-
tide of the exon 2 donor splice site, we hypothesized that this muta-
tion would also be predicted to affect splicing of SEC23B (Table 2).
When we ampliﬁed the cDNA of the patient, no additional band on
agarose gel was highlighted, leading to the supposition of a complete
RNA decay of this mutated allele. Hence, we found the selective ex-
pression of the c.1489C>T allele in sequenced cDNA (Fig. 2C).
Molecular mechanism of SEC23B hypomorphic genotypes
In order to explain the slight reduction of SEC23B expression in the pa-
tient B-II.1, we studied the effect of c.1404+5G>A mutation on mRNA
processing. Ampliﬁcation of the speciﬁc exon regions, encompassing
themutation, of SEC23B cDNA fromnormalwhole bloodmRNAproduced
a single transcript of the expected size (560 bp). By contrast, cDNA of the
patient highlighted the presence of two bands on agarose gel, one corre-
sponding to the expected size fragment and an additional 90-bp shorter
transcript, due to the skipping of exon 12, as conﬁrmed by sequencing
analysis of aberrant cDNA product (Fig. 3A). QRT-PCR analysis by speciﬁc
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sion when compared to SEC23B full transcript both in the proband
(11%) and in the father (2%) (Fig. 3B). Accordingly, in silico analysis pre-
dicted a slight reduction of the score between wild type and mutated
donor site sequence (Table 2). This incorrectly spliced RNA, however,
retained the correct reading frame and encoded a SEC23B protein lacked
30 amino acids, with a predicted molecular weight of approximately
83 KDa (Fig. 3C).
When we analyzed SEC23A expression in all three patients, we
found an upregulation of approximately 4 and 3 fold in respect with
the paralog SEC23B in patients A-II.1 and B-II.1, respectively. Conversely,
no compensatory effect of SEC23A expression has been found neither in
C-II.1 patient nor in control subjects (Fig. 3D).
Discussion
This study represents the ﬁrst description of molecular mecha-
nisms underlying SEC23B hypomorphic genotypes. The inheritance
pattern of the mutations here described conﬁrms the allelic heteroge-
neity of this condition, as themost of causative variations are inherited
as private mutations. Our analyses suggested that the association of
two hypomorphic alleles led to a strong reduction of SEC23B expres-
sion, without generating severe clinical presentation. Indeed, patients
A-II.1 and B-II.1 exhibited a milder phenotype compared to patient
C-II.1. Of note, they share a clinical presentation comparable with a
previously described CDA II case, characterized by a similar genotype
[4]. On the other side, clinical presentation of patient C-II.1 fully
matched with CDA II cases with one missense and one nonsense mu-
tation, according to previous genotype–phenotype correlation study
[10]. Moreover, themolecularmechanism of this patient could explain
the severe phenotype of some patients with two missense mutations
[10], since other exonic mutations could impair splice sites.Fig. 3. Molecular characterization of the c.1404+5G>Amutation and analysis of SEC23A compen
tient B-II.1 and control subjects. After the ampliﬁcation by PCR, the products were separated on 1
approximately 470 bp (exon-12 skipped transcript). On the left, sequencing analysis of the 470-bp
respect to the reference gene,β-actin, is shown. Patient B-II.1 exhibits a reduced expressionof SEC2
while father's proband shows an intermediate level of expression (B-I.1, 3.13±0.08). Exon-12 skip
0.01). No aberrant transcript was found in the controls (0%). Data are presented asmean±SE. Pan
protein isoformderived fromexon-12 skipped transcript. Below, detectionof SEC23Bprotein is sho
PanelD. SEC23A relative expression respect to SEC23B gene is shown. PatientA-II.1 exhibited a stron
B-II.1 exhibited anupregulation of approximately 3 fold in respectwith the paralog SEC23B (fold ch
in patient C-II.1 (fold change 1.07±0.01). Data are presented as mean±SE.We proposed a compensatory mechanism SEC23A-mediated which
could balance the reduced expression of its paralog in those patients
with low SEC23B expression. Taken together, our observations explain
how a fully hypomorphic genotype could result in a milder CDA II phe-
notype. Moreover, they conﬁrm the hypothesis that the total absence of
SEC23 proteins is supposed to be lethal. This is in agreement with stud-
ies on zebraﬁsh morphants which showed that both Sec23 genes carry
speciﬁc but partially redundant roles, at least in craniofacial cartilage
maturation [11]. However, it seems that COPII-related disorders could
be also due to the defective transport of special tissue-speciﬁc cargoes
beyond to the differential, tissue-speciﬁc expression of COPII paralogs
[12]. Understanding of the role of SEC23A–B paralogs in humans
may provide a means of therapeutic intervention by modulating
their expression.
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